ASLN — Aslan Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.13m
- -$2.36m
Annual income statement for Aslan Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 3 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 2.59 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 42.3 | 48.6 | 16.3 | 31.5 | 47.9 |
| Operating Profit | -42.3 | -45.6 | -16.3 | -31.5 | -47.9 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.2 | -46.7 | -17 | -31.6 | -51.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -42.2 | -47.1 | -17 | -31.6 | -51.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.2 | -47 | -16.2 | -31.3 | -51.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.2 | -47 | -16.2 | -31.3 | -51.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -11.3 | -7.87 | -3.4 | -4.13 | -5.9 |
| Dividends per Share |